keyword
https://read.qxmd.com/read/38019772/the-magma-pipeline-for-comprehensive-genomic-analyses-of-clinical-mycobacterium-tuberculosis-samples
#21
JOURNAL ARTICLE
Tim H Heupink, Lennert Verboven, Abhinav Sharma, Vincent Rennie, Miguel de Diego Fuertes, Robin M Warren, Annelies Van Rie
BACKGROUND: Whole genome sequencing (WGS) holds great potential for the management and control of tuberculosis. Accurate analysis of samples with low mycobacterial burden, which are characterized by low (<20x) coverage and high (>40%) levels of contamination, is challenging. We created the MAGMA (Maximum Accessible Genome for Mtb Analysis) bioinformatics pipeline for analysis of clinical Mtb samples. METHODS AND RESULTS: High accuracy variant calling is achieved by using a long seedlength during read mapping to filter out contaminants, variant quality score recalibration with machine learning to identify genuine genomic variants, and joint variant calling for low Mtb coverage genomes...
November 2023: PLoS Computational Biology
https://read.qxmd.com/read/38004523/a-single-run-hplc-ms-multiplex-assay-for-therapeutic-drug-monitoring-of-relevant-first-and-second-line-antibiotics-in-the-treatment-of-drug-resistant-tuberculosis
#22
JOURNAL ARTICLE
Niklas Köhler, Hande Karaköse, Hans-Peter Grobbel, Doris Hillemann, Sönke Andres, Christina König, Barbara Kalsdorf, Thomas Theo Brehm, Laura Böttcher, Inna Friesen, Harald Hoffmann, Dražen Strelec, Dagmar Schaub, Charles A Peloquin, Stefan Schmiedel, Laurent A Decosterd, Eva Choong, Sebastian G Wicha, Rob E Aarnoutse, Christoph Lange, Patricia M Sánchez Carballo
The treatment of drug-resistant Mycobacterium tuberculosis relies on complex antibiotic therapy. Inadequate antibiotic exposure can lead to treatment failure, acquired drug resistance, and an increased risk of adverse events. Therapeutic drug monitoring (TDM) can be used to optimize the antibiotic exposure. Therefore, we aimed to develop a single-run multiplex assay using high-performance liquid chromatography-mass spectrometry (HPLC-MS) for TDM of patients with multidrug-resistant, pre-extensively drug-resistant and extensively drug-resistant tuberculosis...
October 27, 2023: Pharmaceutics
https://read.qxmd.com/read/38003836/pediatric-drug-resistant-tuberculosis-the-current-and-future-prospects-for-management-and-prevention
#23
REVIEW
Dhanya Dharmapalan, Sushant Satish Mane
In the continued battle against one of the oldest enemies known to mankind, Mycobacterium tuberculosis (MTB) , the emergence of drug resistance to antituberculosis drugs among children poses multiple challenges for early detection and treatment. Molecular diagnostics and newer drugs like bedaquiline and delamanid have strengthened the armamentarium and helped design convenient, safe, and child-friendly therapeutic regimens against drug-resistant tuberculosis (TB). Preventive strategies like treatment of TB infection among children living in close contact with patients with drug-resistant TB and effective vaccines against TB are currently in the investigative stages of development and implementation...
November 20, 2023: Pathogens
https://read.qxmd.com/read/37962987/impact-of-prior-tb-treatment-with-new-companion-drugs-on-clinical-outcomes-in-patients-receiving-concomitant-bedaquiline-and-delamanid-for-mdr-rr-tb
#24
JOURNAL ARTICLE
L Mikiashvili, R R Kempker, Ts Chakhaia, N Bablishvili, Z Avaliani, N Lomtadze, M C Schechter, M Kipiani
BACKGROUND: There is scarce data on the clinical outcomes of persons retreated with new/companion anti-tuberculosis (TB) drugs for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). We sought to evaluate the efficacy and safety of bedaquiline and delamanid containing regimens among patients with and without prior exposure to the new/companion drugs (bedaquiline, delamanid, linezolid, clofazimine, and fluoroquinolones). METHODS: We conducted a retrospective cohort study among patients with pulmonary MDR/RR-TB in Georgia who received bedaquiline and delamanid combination as a part of a salvage regimen from November 2017 to December 2020 in a programmatic setting...
November 14, 2023: Clinical Infectious Diseases
https://read.qxmd.com/read/37956677/emergence-of-bedaquiline-resistant-tuberculosis-and-of-multidrug-resistant-and-extensively-drug-resistant-mycobacterium-tuberculosis-strains-with-rpob-ile491phe-mutation-not-detected-by-xpert-mtb-rif-in-mozambique-a-retrospective-observational-study
#25
JOURNAL ARTICLE
Ivan Barilar, Tatiana Fernando, Christian Utpatel, Cláudio Abujate, Carla Maria Madeira, Benedita José, Claudia Mutaquiha, Katharina Kranzer, Tanja Niemann, Nalia Ismael, Leonardo de Araujo, Thierry Wirth, Stefan Niemann, Sofia Viegas
BACKGROUND: In 2021, an estimated 4800 people developed rifampicin-resistant tuberculosis in Mozambique, 75% of which went undiagnosed. Detailed molecular data on rifampicin-resistant and multidrug-resistant (MDR) tuberculosis are not available. Here, we aimed at gaining precise data on the determinants of rifampicin-resistant and MDR tuberculosis in Mozambique. METHODS: In this retrospective observational study, we performed whole-genome sequencing of 704 rifampicin-resistant Mycobacterium tuberculosis complex (Mtbc) strains submitted to the National Tuberculosis Reference Laboratory (NTRL) in Maputo, Mozambique, between 2015 and 2021...
November 10, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/37946698/optimizing-the-design-of-a-pharmacokinetic-trial-to-evaluate-the-dosing-scheme-of-a-novel-tuberculosis-drug-in-children-living-with-or-without-hiv
#26
JOURNAL ARTICLE
Grace Montepiedra, Elin M Svensson, Weng Kee Wong, Andrew C Hooker
Pharmacokinetic (PK) studies in children are usually small and have ethical constraints due to the medical complexities of drawing blood in this special population. Often population PK models for the drug(s) of interest are available in adults, and these models can be extended to incorporate the expected deviations seen in children. As a consequence, there is increasing interest in the use of optimal design methodology to design PK sampling schemes in children that maximize information using a small sample size and limited number of sampling times per dosing period...
November 10, 2023: CPT: Pharmacometrics & Systems Pharmacology
https://read.qxmd.com/read/37922367/tuberculosis-in-spain-an-opinion-paper
#27
REVIEW
S Moreno Guillén, F J Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, B Santiago, J A Caminero, C Barros, D García de Viedma, C Martín, E Bouza
This document is the result of the deliberations of the Committee on Emerging Pathogens and COVID-19 of the Illustrious Official College of Physicians of Madrid (ICOMEM) regarding the current situation of tuberculosis, particularly in Spain. We have reviewed aspects such as the evolution of its incidence, the populations currently most exposed and the health care circuits for the care of these patients in Spain. We have also discussed latent tuberculosis, the reality of extrapulmonary disease in the XXI century and the means available in daily practice for the diagnosis of both latent and active forms...
November 2, 2023: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://read.qxmd.com/read/37914420/-expert-consensus-on-off-label-use-of-antituberculosis-drugs-2023-update
#28
JOURNAL ARTICLE
(no author information available yet)
In 2018, Chinese Society of Tuberculosis, Chinese Medical Association organized and wrote the Expert consensus on off-label use of antituberculosis drugs , which covered more comprehensively the contents related to off-label use of antituberculosis drugs, and was the basis for clinical workers to exceed the drug instructions for the use of antituberculosis treatment in irreplaceable cases, and was also a good regulation for off-label use, which had a great guiding effect on clinical work. In the last four years, with the reported national and international research results, the anti-tuberculosis treatment drugs have been adjusted and there are more new advances in the use of some drugs...
November 12, 2023: Chinese Journal of Tuberculosis and Respiratory Diseases
https://read.qxmd.com/read/37880886/a-novel-home-based-method-for-preparing-suspensions-of-anti-tb-drugs
#29
JOURNAL ARTICLE
R Taneja, M C Nahata, J Scarim, P G Pande, A Scarim, G Hoddinott, C L Fourie, R K Jew, H S Schaaf, A C Hesseling, A J Garcia-Prats, K Rao Inabathina
BACKGROUND: Tablets are the most widely available dosage form for the treatment of TB; however, adult tablets fail to meet the needs of young children who cannot swallow these tablets or require dose titration. We tested a new, simple device (XTEMP-R® ) and the methodology for converting tablets of TB drugs into a homogeneous suspension for home use by children and caregivers. METHODS: XTEMP-R is a new device used for converting tablets into liquid preparations. Four TB drugs - pretomanid, delamanid, clofazimine and bedaquiline - were dispersed in the device utilizing water and simple syrup...
November 1, 2023: International Journal of Tuberculosis and Lung Disease
https://read.qxmd.com/read/37814826/evaluation-of-2-3-dihydroimidazo-2-1-b-oxazole-and-imidazo-2-1-b-oxazole-derivatives-as-chemotherapeutic-agents
#30
REVIEW
Afnan I Shahin, Seyed-Omar Zaraei, Shahed Alzuraiqi, Zahaa Abdulateef, Noora E Abbas, Taleb H Al-Tel, Mohammed I El-Gamal
Imidazo[2,1- b ]oxazole and 2,3-dihydroimidazo[2,1- b ]oxazole ring systems are commonly employed in therapeutically active molecules. In this article, the authors review the utilization of these core scaffolds as chemotherapeutic agents from 2018 to 2022. These scaffolds possess many important biological activities including antimicrobial and anticancer, among others. This review covers their biological activities and structure-activity relationships. One of the most important drugs in this class of compounds is the antitubercular agent delamanid...
October 10, 2023: Future Medicinal Chemistry
https://read.qxmd.com/read/37773767/estimating-post-treatment-recurrence-after-multidrug-resistant-tuberculosis-treatment-among-patients-with-and-without-hiv-the-impact-of-assumptions-about-death-and-missing-follow-up
#31
JOURNAL ARTICLE
Sara M Sauer, Carole D Mitnick, Uzma Khan, Catherine Hewison, Mathieu Bastard, David Holtzman, Stephanie Law, Munira Khan, Shrivani Padayachee, Saman Ahmed, Afshan K Isani, Aga Krisnanda, Stalz Charles Vilbrun, Sagit Bektasov, Andargachew Kumsa, Wisney Docteur, Karen Tintaya, Mark McNicol, Hakob Atshemyan, Tatiana Voynilo, Thin Thin Thwe, Kwonjune Seung, Michael Rich, Helena Huerga, Palwasha Khan, Molly Franke
BACKGROUND: Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). However, such analyses are complicated when some patients die or become lost during post-treatment-follow-up. METHODS: We analyzed data on 1,991 patients who successfully completed a longer MDR/RR-TB regimen containing bedaquiline and/or delamanid between 2015 and 2018 in 16 countries. Using five approaches for handling post-treatment deaths, we estimated the six-month post-treatment TB recurrence risk overall, and by HIV status...
September 29, 2023: Clinical Infectious Diseases
https://read.qxmd.com/read/37753014/drug-resistance-in-osteoarticular-tuberculosis-a-study-from-an-endemic-zone
#32
JOURNAL ARTICLE
Amartya Gain, Anil K Jain, Manpreet Bhalla, Aditya N Aggarwal, Ish K Dhammi, Vinod K Arora
The present study was undertaken to determine the incidence of drug resistance against anti-tubercular drugs among patients from an endemic zone.  Methodology: Forty consecutive clinico-radiologically diagnosed patients of osteoarticular tuberculosis (29: spine, 11: extraspinal) were enrolled. Pus from needle aspiration was taken in 31 cases, tissue following spinal decompression in seven, synovial in one, and sinus edge biopsy in one. The pus/tissue was subjected to acid-fast bacilli (AFB) staining and liquid culture, sensitivity to 13 anti-tubercular drugs (Isoniazid (INH), rifampicin (RIF), kanamycin (KAN), amikacin (AMK,) capreomycin (CAP), ethionamide (ETH), levofloxacin (LEV), moxifloxacin (MOX), linezolid (LNZ), para-amino-salicylic acid (PAS), bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFO)) were checked, and histopathological/cytopathological examination and molecular tests were performed...
August 2023: Curēus
https://read.qxmd.com/read/37740935/investigation-of-genomic-mutations-and-their-association-with-phenotypic-resistance-to-new-and-repurposed-drugs-in-mycobacterium-tuberculosis-complex-clinical-isolates
#33
JOURNAL ARTICLE
Simone Mok, Emma Roycroft, Peter R Flanagan, Johannes Wagener, Margaret M Fitzgibbon
BACKGROUND: WGS has the potential to detect resistance-associated mutations and guide treatment of MDR TB. However, the knowledge base to confidently interpret mutations associated with the new and repurposed drugs is sparse, and phenotypic drug susceptibility testing is required to detect resistance. METHODS: We screened 900 Mycobacterium tuberculosis complex genomes from Ireland, a low TB incidence country, for mutations in 13 candidate genes and assessed their association with phenotypic resistance to bedaquiline, clofazimine, linezolid, delamanid and pretomanid...
September 23, 2023: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/37732780/insight-into-the-drug-resistant-characteristics-and-genetic-diversity-of-multidrug-resistant-mycobacterium-tuberculosis-in-china
#34
JOURNAL ARTICLE
Zexuan Song, Chunfa Liu, Wencong He, Shaojun Pei, Dongxin Liu, Xiaolong Cao, Yiting Wang, Ping He, Bing Zhao, Xichao Ou, Hui Xia, Shengfen Wang, Yanlin Zhao
Multidrug-resistant tuberculosis (MDR-TB) has a severe impact on public health. To investigate the drug-resistant profile, compensatory mutations and genetic variations among MDR-TB isolates, a total of 546 MDR-TB isolates from China underwent drug-susceptibility testing and whole genome sequencing for further analysis. The results showed that our isolates have a high rate of fluoroquinolone resistance (45.60%, 249/546) and a low proportion of conferring resistance to bedaquiline, clofazimine, linezolid, and delamanid...
September 21, 2023: Microbiology Spectrum
https://read.qxmd.com/read/37681559/pre-xdr-congenital-tuberculosis-in-an-extremely-premature-baby
#35
JOURNAL ARTICLE
Alison Boast, Jeu Ann How, Charis Lau, Arun Sett, Damian Gilby, Andrew Burke, Brett McWhinney, Connor Wright, Adrian Tramontana, Maria Globan, Justin Denholm, Stephen M Graham, Joshua Osowicki
We describe a case of congenital tuberculosis in an extremely premature baby, with rapid molecular detection of a pre-XDR pattern of drug resistance. The baby was treated successfully with a regimen including bedaquline and delamanid, drugs not previously described in the treatment of congenital TB.
September 8, 2023: Clinical Infectious Diseases
https://read.qxmd.com/read/37606512/pregnancy-and-birth-outcomes-in-patients-with-multidrug-resistant-tuberculosis-treated-with-regimens-that-include-new-and-repurposed-drugs
#36
JOURNAL ARTICLE
Ismat Lotia Farrukh, Nathalie Lachenal, Malik M Adenov, Saman Ahmed, Yerkebulan Algozhin, Sylvine Coutisson, Epifanio Sánchez Garavito, Catherine Hewison, David Holtzman, Helena Huerga, Aleeza Janmohamed, Palwasha Y Khan, Gamarly Leblanc Jacques, Nino Lomtadze, Nara Melikyan, Carole D Mitnick, Gulnaz Mussabekova, Elna Osso, Sara Perea, Fauziah Asnely Putri, Mahmud Rashidov, Michael L Rich, Yekaterina Sakhabutdinova, Kwonjune J Seung, Assel Stambekova, Dante Vargas Vásquez, Molly F Franke, Uzma Khan
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.
August 22, 2023: Clinical Infectious Diseases
https://read.qxmd.com/read/37578286/formulation-and-scale-up-of-delamanid-nanoparticles-via-emulsification-for-oral-tuberculosis-treatment
#37
JOURNAL ARTICLE
Nicholas J Caggiano, Madeleine S Armstrong, Joanna S Georgiou, Aditya Rawal, Brian K Wilson, Claire E White, Rodney D Priestley, Robert K Prud'homme
Delamanid (DLM) is a hydrophobic small molecule therapeutic used to treat drug-resistant tuberculosis (DR-TB). Due to its hydrophobicity and resulting poor aqueous solubility, formulation strategies such as amorphous solid dispersions (ASDs) have been investigated to enhance its aqueous dissolution kinetics and thereby improve oral bioavailability. However, ASD formulations are susceptible to temperature- and humidity-induced phase separation and recrystallization under harsh storage conditions typically encountered in areas with high tuberculosis incidence...
August 14, 2023: Molecular Pharmaceutics
https://read.qxmd.com/read/37576289/surveillance-of-multidrug-resistant-tuberculosis-in-sub-saharan-africa-through-wastewater-based-epidemiology
#38
JOURNAL ARTICLE
Hlengiwe N Mtetwa, Isaac D Amoah, Sheena Kumari, Faizal Bux, Poovendhree Reddy
The spread of multidrug-resistant tuberculosis (MDR-TB) is a serious public health issue, particularly in developing nations. The current methods of monitoring drug-resistant TB (DR-TB) using clinical diagnoses and hospital records are insufficient due to limited healthcare access and underreporting. This study proposes using Wastewater-Based Epidemiology (WBE) to monitor DR-TB in six African countries (Ghana, Nigeria, Kenya, Uganda, Cameroon, and South Africa) and examines the impact of treated wastewater on the spread of TB drug-resistant genes in the environment...
August 2023: Heliyon
https://read.qxmd.com/read/37517627/the-effect-of-anti-tuberculosis-drug-pharmacokinetics-on-qtc-prolongation
#39
JOURNAL ARTICLE
Yutong Jin, David Benkeser, Maia Kipiani, Nicole F Maranchick, Lali Mikiashvili, Ketevan Barbakadze, Zaza Avaliani, Wael A Alghamdi, Mohammad H Alshaer, Charles A Peloquin, Henry M Blumberg, Russell R Kempker
BACKGROUND: Implementation of newer anti-tuberculosis (TB) drugs may prolong the QT interval, increasing the risk of arrythmias and sudden cardiac death. The potential for cardiac adverse events has prompted recommendations for frequent cardiac monitoring during treatment. However, unknowns remain, including the association between drug concentrations and QT interval. METHODS: An observational prospective cohort study design was used. Patients undergoing treatment for drug-resistant TB in Georgia were assessed...
July 29, 2023: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/37482332/recent-advances-in-the-treatment-of-tuberculosis
#40
REVIEW
Ilaria Motta, Martin Boeree, Dumitru Chesov, Keertan Dheda, Gunar Günther, Charles Robert Horsburgh, Yousra Kherabi, Christoph Lange, Christian Lienhardt, Helen M McIlleron, Nicholas I Paton, Helen R Stagg, Guy Thwaites, Zarir Udwadia, Reinout Van Crevel, Gustavo E Velásquez, Robert J Wilkinson, Lorenzo Guglielmetti
BACKGROUND: Tuberculosis (TB) is a global health challenge and one of the leading causes of death worldwide. In the last decade, the TB treatment landscape has dramatically changed. After long years of stagnation, new compounds entered the market (bedaquiline, delamanid, and pretomanid) and phase III clinical trials have shown promising results towards shortening duration of treatment for both drug-susceptible (Study 31/A5349, TRUNCATE-TB, and SHINE) and drug-resistant TB (STREAM, NiX-TB, ZeNix, and TB-PRACTECAL)...
July 22, 2023: Clinical Microbiology and Infection
keyword
keyword
64447
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.